Immunic, Inc. (NASDAQ:IMUX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Immunic, Inc. (NASDAQ:IMUX) have been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.50.

Several research firms recently weighed in on IMUX. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Friday, September 26th. Chardan Capital began coverage on shares of Immunic in a research note on Monday, September 29th. They set a “buy” rating and a $13.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunic in a research note on Saturday, September 27th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $10.00 target price on shares of Immunic in a research note on Thursday, September 25th.

Immunic Price Performance

Shares of NASDAQ IMUX opened at $0.98 on Monday. The firm has a fifty day moving average price of $0.89 and a 200-day moving average price of $0.91. The stock has a market cap of $96.51 million, a PE ratio of -1.04 and a beta of 1.56. Immunic has a 1 year low of $0.56 and a 1 year high of $1.73.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). On average, research analysts expect that Immunic will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Immunic

Several institutional investors have recently bought and sold shares of the business. Aberdeen Group plc lifted its position in Immunic by 678.1% during the second quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after purchasing an additional 7,184,457 shares during the last quarter. Focus Partners Wealth lifted its holdings in shares of Immunic by 19.1% in the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock worth $2,816,000 after acquiring an additional 415,104 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Immunic by 279.3% in the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock worth $226,000 after acquiring an additional 152,726 shares during the last quarter. 683 Capital Management LLC lifted its holdings in shares of Immunic by 28.6% in the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $981,000 after acquiring an additional 200,000 shares during the last quarter. Finally, Millennium Management LLC increased its stake in Immunic by 480.6% in the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after buying an additional 479,846 shares during the period. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.